Webinar

Understanding Rabies Prevention: Why HRIG Volume Matters

Date: October 13, 2020

Time: 12:00 PM EDT

Duration: 30 Minutes

In our webinar, Understanding Rabies Prevention: Why HRIG Volume Matters where we take an in-depth look at some of the recent changes in the human rabies immune globulin (HRIG) market as well as provide educational information about rabies and rabies post-exposure prophylaxis (PEP).

 

The webinar covers the following key areas:

  • Rabies, one of the oldest and deadliest diseases1,2
  • Rabies PEP
  • A video of a patient being administered HRIG
  • Clinical implications of double-concentration HRIG
  • Why HRIG volume matters
  • KEDRAB® (Rabies Immune Globulin [Human]) clinical overview

Presenters:

Peter J. Costa, MPH, MCHES, AVES (Hon)

Current Roles

  • Rabies Ig Brand Director, Kedrion Biopharma
  • Member, Rabies in the Americas Steering Committee
  • Reviewer, PLOS Neglected Tropical Diseases
  • Associate Executive Director, One Health Commission

 

Previous Roles

  • Director, Health Advancement & Prevention Strategies, Lehigh University
  • Director, Education and Outreach, Global Alliance for Rabies Control
  • Founding Member and Global Campaign Coordinator, World Rabies Day
  • Public Health Educator, North Carolina DHHS

 

Dr. Jerry Siegel, PharmD, FASHP

Dr. Siegel is compensated by Kedrion Biopharma for his involvement in this program.

 

Current Roles

  • VP, Managing Partner of Safe Medication Management Associates, Inc.
  • Clinical Associate Professor, The Ohio State University College of Pharmacy

 

Previous Roles

  • Senior Director for Pharmaceutical Service, The Ohio State University Center
  • Assistant Dean of Medical Center Affairs, The Ohio State University College of Pharmacy
  • President, The Ohio Society of Health System Pharmacists

Complete the form to register

Required *








Terms and Conditions: Kedrion Biopharma Inc. (“Kedrion Biopharma”) respects the privacy of your personal information. Kedrion Biopharma, and companies providing services to Kedrion Biopharma, may use the information that you provide to send you marketing or informational materials, analyze and use your information to improve or develop services and programs, and contact you about marketing programs or research about health topics that may be of interest to you.

Kedrion Biopharma, and companies providing services to Kedrion Biopharma, will not sell or rent your personally identifiable information. For more information regarding our Privacy Policy, click here.

References: 1. Scott TP, Nel LH. Subversion of the immune response by rabies virus. Viruses. 2016;8(8):E231. 2. Fooks AR, Banyard AC, Horton DL, Johnson N, McElhinney LM, Jackson AC. Current status of rabies and prospects for elimination. Lancet. 2014;384:1389-1399.